Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (423)

Search Parameters:
Keywords = teratogens

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
23 pages, 1820 KB  
Article
The Genetic and Embryo–Fetal Developmental Toxicity Profile of the Novel Transgelin Agonist Deg-AZM: Ames, Micronucleus, Chromosomal Aberration, and Rat EFD Studies
by Xiaoting Gu, Ying Xu, Nannan Liu, Keran Li, Xiaoting Wang, Jia Zhang, Xiaoting Zhang, Yanjie Ding, Xiaohe Li, Honggang Zhou, Xiaoyu Ai and Cheng Yang
Biomedicines 2025, 13(11), 2600; https://doi.org/10.3390/biomedicines13112600 - 23 Oct 2025
Viewed by 278
Abstract
Background: Slow-transit constipation (STC) lacks durable and safe prokinetics. Deglycosylated-azithromycin (Deg-AZM), a novel small-molecule transgelin agonist that restores colonic motility in STC, has been approved for clinical trials in 2024. Objectives: This study aimed to assess the genetic toxicity and embryo–fetal development (EFD) [...] Read more.
Background: Slow-transit constipation (STC) lacks durable and safe prokinetics. Deglycosylated-azithromycin (Deg-AZM), a novel small-molecule transgelin agonist that restores colonic motility in STC, has been approved for clinical trials in 2024. Objectives: This study aimed to assess the genetic toxicity and embryo–fetal development (EFD) toxicity of Deg-AZM through a series of standardized non-clinical safety studies. Methods: We conducted Ames, in vivo micronucleus, and chromosomal aberration tests to evaluate genotoxicity. Acute and 28-day repeated-dose oral toxicity studies were performed in Sprague-Dawley rats. EFD toxicity was assessed in pregnant rats administered Deg-AZM from gestation day (GD) 6 to 15. Toxicokinetic analyses were integrated into repeated-dose and EFD studies. Results: Deg-AZM demonstrated no mutagenic potential in the bacterial reverse-mutation assay at concentrations up to 2500 µg/plate (with metabolic activation) or 150 µg/plate (without metabolic activation). No clastogenic effects were observed in micronucleus or chromosomal aberration assays. The median lethal dose (LD50) exceeded 1600 mg/kg in acute oral toxicity. In the 28-day study, no adverse effects were observed at doses up to 600 mg/kg, though mild hematological and hepatic changes were noted at high doses, all of which were reversible. In the EFD study, Deg-AZM did not induce maternal toxicity, teratogenicity, or adverse fetal outcomes at doses up to 600 mg/kg. Conclusions: Deg-AZM demonstrates a favorable safety profile with no evidence of genetic toxicity or developmental harm at pharmacologically relevant doses, supporting its further development as a therapeutic agent for STC. Full article
(This article belongs to the Section Drug Discovery, Development and Delivery)
Show Figures

Figure 1

28 pages, 1478 KB  
Review
Safety Assessment of Stem Cell-Based Therapies: Current Standards and Advancing Frameworks
by Georgy E. Leonov, Lydia R. Grinchevskaya, Oleg V. Makhnach, Marina V. Samburova, Dmitry V. Goldshtein and Diana I. Salikhova
Cells 2025, 14(21), 1660; https://doi.org/10.3390/cells14211660 - 23 Oct 2025
Viewed by 385
Abstract
Regenerative medicine is a rapidly evolving field of contemporary biomedical research that offers new therapeutic strategies for conditions previously considered untreatable. Cell therapy shows particular potential in this domain. However, rigorous biosafety measures are required in its development and clinical application. This review [...] Read more.
Regenerative medicine is a rapidly evolving field of contemporary biomedical research that offers new therapeutic strategies for conditions previously considered untreatable. Cell therapy shows particular potential in this domain. However, rigorous biosafety measures are required in its development and clinical application. This review proposes a practice-oriented biosafety framework for cell therapy, translating key risks into operational principles: toxicity, oncogenicity/tumorigenicity/teratogenicity, immunogenicity, biodistribution; and cell product quality. For each principle, preclinical approaches and regulatory expectations are summarized. Criteria for immunological safety are addressed, including activation of innate immunity (complement, T- and NK-cell responses) and the need for HLA typing. Biodistribution assessment involves the use of quantitative PCR and imaging techniques (PET, MRI) to monitor cell fate over time. The risks of oncogenicity, tumorigenicity, and teratogenicity can be analyzed using a combination of in vitro methods and in vivo models in immunocompromised animals. Product quality assessment includes sterility, identity, potency, viability, and genetic stability, with alignment of procedures to regulatory requirements and an emphasis on quality-by-design principles to ensure safe and reproducible clinical use. Integrating toxicity and safety pharmacology data supports a balanced risk–benefit assessment and clinical trial planning. Full article
(This article belongs to the Special Issue Advances and Breakthroughs in Stem Cell Research)
Show Figures

Figure 1

19 pages, 1030 KB  
Article
Zebrafish Embryo Developmental Toxicity Assay (ZEDTA) for Regulatory Testing—Protocol Optimization and Historical Control Data
by Daphne van den Oetelaar, Marysia Agnieszka Tobor-Kapłon, Mèlanie Reijnaers and Manon Beekhuijzen
Toxics 2025, 13(10), 874; https://doi.org/10.3390/toxics13100874 - 14 Oct 2025
Viewed by 500
Abstract
The Zebrafish Embryo Developmental Toxicity Assay (ZEDTA) is a promising and innovative method with potential to replace the screening of teratogenic substances in mammals during preclinical development. However, a harmonized and validated protocol does not exist for the ZEDTA, and data on the [...] Read more.
The Zebrafish Embryo Developmental Toxicity Assay (ZEDTA) is a promising and innovative method with potential to replace the screening of teratogenic substances in mammals during preclinical development. However, a harmonized and validated protocol does not exist for the ZEDTA, and data on the background incidence of spontaneous malformations are not readily accessible. Therefore, the aim of this research was twofold: (1) to optimize the ZEDTA protocol and (2) to generate historical control data. The most optimal results were achieved by exposing zebrafish larvae in 24-well plates at a temperature of 26 °C in combination with the renewal of test solutions after 48 h of exposure. Furthermore, the use of 0.5% v/v DMSO did not induce more malformations or mortality than exposure to standard ISO medium. In total, 26 valid experiments were conducted using the optimized ZEDTA protocol. An overall mortality of 3.5% was recorded after 96 h of exposure. Malformations were observed in 7.6% of all surviving larvae. The most frequently observed abnormalities included yolk sac deformation (4.0%), followed by tail (2.8%), heart (2.6%), and head malformations (1.6%). The optimized protocol was considered effective in supporting an optimal development rate of exposed zebrafish larvae, with low mortality and minimal background malformations. These findings indicate a low level of confounding factors and high reliability of results, making an essential step in the refinement of ZEDTA toward global harmonization and regulatory acceptance. Full article
(This article belongs to the Section Reproductive and Developmental Toxicity)
Show Figures

Figure 1

16 pages, 776 KB  
Case Report
An Account of Acute Myeloid Leukemia Complicating Pregnancy and Literature Review
by Georgiana Nemeti, Laura Jimbu, Oana Mesaros, Iulian Gabriel Goidescu, Cezara Moisa, Mihai Surcel, Cerasela Mihaela Goidescu, Dan Boitor-Borza, Gheorghe Cruciat, Ioana Cristina Rotar and Daniel Muresan
Diagnostics 2025, 15(19), 2540; https://doi.org/10.3390/diagnostics15192540 - 9 Oct 2025
Viewed by 540
Abstract
Background and Clinical Significance: The occurrence of acute myeloid leukemia (AML) in pregnancy represents a diagnostic and management challenge in the attempt to balance and achieve both maternal and fetal wellbeing. Pregnancy-specific manifestations mimic the initial symptoms of leukemia and may lead to [...] Read more.
Background and Clinical Significance: The occurrence of acute myeloid leukemia (AML) in pregnancy represents a diagnostic and management challenge in the attempt to balance and achieve both maternal and fetal wellbeing. Pregnancy-specific manifestations mimic the initial symptoms of leukemia and may lead to a delay in diagnosis, especially during the first trimester of pregnancy. Decision-making strategies involve the patient and couples counseling with a multidisciplinary team of hematologists, obstetricians, neonatologists and psychologists. Maternal outcome depends on the disease subtype, progression and response to medication. Fetal outcome depends on other potential pregnancy complications, possible teratogenicity, gestational age at delivery and sometimes iatrogenic prematurity. Case Presentation: We present the case of a 38-year-old multiparous patient with a late first trimester, with an AML diagnosis presenting with hyperemesis gravidarum-like symptoms. Genetic testing revealed the presence of an Fms-like tyrosine kinase 3-internal tandem duplication mutation (FLT3-ITD). Following that, a repeatedly refused termination of pregnancy and rapid disease progression with azacitidine therapy was initiated. Elective cesarean delivery was performed at 34 weeks of gestation due to progressive leukocytosis, which persisted postpartum, requiring the use of first-, second-, and eventually third-line chemotherapy. Fetal outcome was favorable at 3 months postpartum. Conclusions: Cases of AML in pregnancy require a tailored approach according to guidelines, but also patient/couple preferences, while the choice of chemotherapy is limited considering its potential teratogenic effects. This is a case with a misleading first presentation and a challenging therapeutic choice due to its genetic subtype and maternal treatment postponement. Full article
(This article belongs to the Section Clinical Diagnosis and Prognosis)
Show Figures

Figure 1

16 pages, 616 KB  
Systematic Review
Pediatric Coccidioidal Meningitis: A Systematic Review and Proportional Synthesis of Cases Reported in the Fluconazole Era (2000–2025)
by Maria F. De la Cerda-Vargas, Pedro Navarro-Dominguez, Elizabeth Meza-Mata, Melisa A. Muñoz-Hernandez, Fany Karina Segura-Lopez, Marisela Del Rocio Gonzalez-Martinez, Hector A. Delgado-Aguirre, Sergio Valente Flores-Miranda, David de Jesús Mercado-Rubio, Yair O. Adame-Martínez, Geovanni A. Valadez-Altamira and Jose Antonio Candelas-Rangel
J. Fungi 2025, 11(10), 713; https://doi.org/10.3390/jof11100713 - 1 Oct 2025
Viewed by 595
Abstract
Coccidioidal meningitis (CM) is a rare but life-threatening complication of disseminated coccidioidomycosis, occurring in ~16% of cases, particularly among children in endemic regions such as the southwestern US and northern Mexico. Without timely diagnosis and antifungal therapy, pediatric CM is almost universally fatal [...] Read more.
Coccidioidal meningitis (CM) is a rare but life-threatening complication of disseminated coccidioidomycosis, occurring in ~16% of cases, particularly among children in endemic regions such as the southwestern US and northern Mexico. Without timely diagnosis and antifungal therapy, pediatric CM is almost universally fatal within the first year. Hydrocephalus develops in up to 50% of cases. In 2000, Galgiani et al. established fluconazole as first-line therapy for CM. Subsequent guidelines refined management but did not specifically address pediatric patients (>1 month–≤19 years). No studies in the fluconazole era have systematically evaluated risk factors for complications in this population. We therefore conducted a systematic review and proportional synthesis of pediatric CM cases, focusing on CNS complications and outcomes. PubMed/MEDLINE, Embase (Ovid), and Web of Science were systematically searched (2000–2025). PROSPERO registration ID (1130290). Inclusion criteria encompassed epidemiological studies, case series, and case reports that described at least one pediatric case of CM or CNS involvement, confirmed by diagnostic methods. Cases in adults, neonates (<1 month), congenital infections, teratogenicity studies, reviews, or incomplete reports were excluded. Only cases with complete individual data (n = 48) were included. Methodological rigor was ensured using JBI Critical Appraisal Tools. Of 1089 studies, 31 met the inclusion criteria, representing 3874 pediatric cases. CM/CNS involvement was confirmed in 165 cases (4.25%; 95% CI: 3.6–4.9%), with hydrocephalus in 62 (37.5%). Among 48 case reports with complete data, fluconazole was first-line therapy in 65%. Serum CF titers ≥ 1:16 were associated with hydrocephalus plus stroke (p = 0.027) and independently predicted adverse outcomes (relapse/death; OR = 4.5, p = 0.037), whereas lifelong azole therapy was associated with improved outcomes (overall survival mean, 82 vs. 32 months; p = 0.002). Pediatric CM remains highly lethal, with hydrocephalus a frequent and severe complication. High serum CF titers (≥1:16) predict poor outcomes, emphasizing the urgent need for standardized, pediatric-specific diagnosis and management guidelines. Full article
(This article belongs to the Special Issue Pediatric Fungal Infections, 2nd Edition)
Show Figures

Figure 1

32 pages, 1701 KB  
Review
Healthcare Waste Toxicity: From Human Exposure to Toxic Mechanisms and Management Strategies
by Ilie Cirstea, Andrei-Flavius Radu, Ada Radu, Delia Mirela Tit and Gabriela S. Bungau
J. Xenobiot. 2025, 15(5), 155; https://doi.org/10.3390/jox15050155 - 25 Sep 2025
Viewed by 1110
Abstract
Healthcare waste (HCW) represents a growing yet frequently underestimated threat to public health, due to its complex toxicological profile. Exposure to HCW has been associated with a broad spectrum of adverse effects, including infections of bacterial, viral, or fungal origin, as well as [...] Read more.
Healthcare waste (HCW) represents a growing yet frequently underestimated threat to public health, due to its complex toxicological profile. Exposure to HCW has been associated with a broad spectrum of adverse effects, including infections of bacterial, viral, or fungal origin, as well as systemic consequences such as endocrine disruption, metabolic disturbances, and mutagenic, carcinogenic, or teratogenic outcomes. These risks are particularly elevated among healthcare professionals and waste management personnel, who are directly exposed to hazardous materials. This narrative review aims to consolidate current knowledge on the toxic potential of HCW, emphasizing the variability of risks according to waste category and point of origin. A critical reevaluation of the toxicity–health risk–waste management triad is needed to strengthen preventive and protective strategies in both clinical and waste-handling settings, and the review is therefore structured around targeted questions along this axis. Priority should be given to waste prevention, minimization, and segregation at source, as downstream treatment processes may introduce additional hazards. Each category of hazardous HCW exhibits specific mechanisms of toxicity, underlining the importance of targeted and informed management approaches. Future directions should include enhanced training for waste handlers, the development of unified regulatory frameworks, and improved international data collection and reporting systems. Strengthening these components is essential for reducing occupational and environmental health risks and ensuring safer conditions across healthcare systems. Full article
Show Figures

Graphical abstract

15 pages, 1249 KB  
Review
Effects of Phytocannabinoids on Reproductive System and Prenatal Development: Mechanisms and Clinical Implications
by Michał Wesołowski, Aleksandra Sobaś, Kamil Biedka, Jakub Karwacki, Jakub Bulski, Katarzyna Błaszczyk, Kacper Żełabowski, Oliwia Ziobro, Filip Jacek Maj, Karol Sornat, Agata Estreicher, Anna Klasa, Andrzej Dłubak and Tadeusz Sebzda
J. Clin. Med. 2025, 14(18), 6494; https://doi.org/10.3390/jcm14186494 - 15 Sep 2025
Viewed by 1604
Abstract
Cannabis is one of the most studied psychoactive substances due to its increasing prevalence and evolving legal status. Of particular concern is the rising consumption among young individuals, where excessive use may disrupt reproductive processes and pose long-term health risks to offspring. This [...] Read more.
Cannabis is one of the most studied psychoactive substances due to its increasing prevalence and evolving legal status. Of particular concern is the rising consumption among young individuals, where excessive use may disrupt reproductive processes and pose long-term health risks to offspring. This narrative review examines the effects of cannabis use on male and female reproductive health, including its impact on male fertility, the female reproductive system, placental function, and prenatal and postnatal outcomes, as well as fetal development. A nonsystematic review was conducted using PubMed, Scopus, Web of Science, and Google Scholar databases in November 2024. After screening titles and abstracts and the full-text analysis, 64 studies were included in this narrative review. In men, cannabinoids can interfere with spermatogenesis, reduce sperm motility and quality, and lower testosterone levels, as demonstrated in clinical and experimental studies. In women, cannabinoid-induced disorders include negative effects on ovarian follicle maturation, ovulation, placental function, and prenatal development. Prenatal exposure to cannabis is associated with the risk of reduced birth weight, birth defects, sudden infant death syndrome (SIDS) or lactation problems due to the penetration of cannabis metabolites into breast milk. The findings highlight the potential negative effects of cannabis on reproductive health and fetal development. Given these risks, individuals attempting to conceive, and pregnant women should be advised against cannabis use. Greater awareness is needed among healthcare professionals and the public regarding the reproductive risks associated with cannabis consumption. While the evidence on teratogenic effects is not always conclusive, caution should be exercised, and further research is essential to deepen the understanding of these effects. Full article
Show Figures

Figure 1

10 pages, 1019 KB  
Article
Morphological and Behavioral Abnormalities Induced by Hydrogen Peroxide in Drosophila melanogaster
by María Llasbeth Hernández-Calderón, Alondra Gallegos-Moreno, Aneet Yamely Miranda-Camacho, Claudia Linette Sánchez-Jiménez, Sandra Díaz-Barriga-Arceo, Jorge Alejandro Aguirre-Joya, Cristian Torres-León and David Ramiro Aguillón-Gutiérrez
Biology 2025, 14(9), 1122; https://doi.org/10.3390/biology14091122 - 25 Aug 2025
Viewed by 814
Abstract
Congenital developmental defects are among the postnatal consequences of early exposure to hydrogen peroxide or other teratogens that induce oxidative stress, highlighting a potential mechanistic link between oxidative stress, redox signaling, and developmental processes. This study evaluated the morphological and behavioral abnormalities induced [...] Read more.
Congenital developmental defects are among the postnatal consequences of early exposure to hydrogen peroxide or other teratogens that induce oxidative stress, highlighting a potential mechanistic link between oxidative stress, redox signaling, and developmental processes. This study evaluated the morphological and behavioral abnormalities induced by hydrogen peroxide in the Drosophila melanogaster model, as well as its teratogenic index. The results demonstrated that hydrogen peroxide induces morphological abnormalities in adult wings, legs, and abdomen, as well as necrosis and developmental disruptions during larval and pupal stages. A median lethal concentration (LC50) of 0.16% and a teratogenic index (TI) of 0.44 were calculated when considering anomalies at any development stage; a TI of 0.21 was obtained when considering only adult abnormalities. Regarding behavioral changes, an increase in locomotor activity was observed in both larvae and adults, with significantly greater activity recorded in adult females than in males. These findings suggest that hydrogen peroxide can induce both morphological and behavioral abnormalities in D. melanogaster, although it presents a low teratogenic index. Full article
(This article belongs to the Special Issue Animal Models in Toxicology)
Show Figures

Figure 1

21 pages, 12120 KB  
Article
Integrated Pharmacoepigenomic Analysis Uncovers the Impact of Antiseizure Medications on Developmental Pathways and the Protective Effect of Folic Acid
by Neethu Mohan and Moinak Banerjee
Int. J. Mol. Sci. 2025, 26(16), 7981; https://doi.org/10.3390/ijms26167981 - 19 Aug 2025
Cited by 1 | Viewed by 881
Abstract
Fetal exposure to antiseizure medications (ASMs) can impact organogenesis, resulting in elevated risk of congenital malformations. Despite longstanding clinical awareness of the teratogenic potential of ASMs, the molecular mechanisms remain largely unexplored. To address this multisystem impact of ASMs, an OMIC-based approach was [...] Read more.
Fetal exposure to antiseizure medications (ASMs) can impact organogenesis, resulting in elevated risk of congenital malformations. Despite longstanding clinical awareness of the teratogenic potential of ASMs, the molecular mechanisms remain largely unexplored. To address this multisystem impact of ASMs, an OMIC-based approach was considered to understand the impact of ASMs on methylome and subsequently on proteome and how folic acid (FA) supplementation can counter the teratogenic impact. The study employed an established in vitro embryonic cell line model system, treated with varying concentrations of first-generation ASMs, alone and in combination with FA. Integrated analyses included quantification of global DNA methylation, expression analysis of key epigenetic regulators (DNMTs and TETs), genome-wide methylation profiling using the 935K EPIC array, and LC-MS/MS-based proteomics analysis. The study identified that ASMs can induce global DNA hypomethylation, which was likely to be impacted by dysregulation of DNMT and TET expression. Interestingly, FA co-treatment partially restored DNA methylation as evidenced by global DNA methylation and epigenetic gene expression, and also by compensatory effect via one-carbon metabolism. Genome-wide DNA methylation revealed site-specific hypermethylation at key developmental genes, several of which were reversed with FA. Proteomics analysis identified downregulation of developmentally critical proteins, including those linked to key metabolic processes, while FA co-treatment reversed expression of several such proteins. Integrative methylome–proteome analysis revealed the coordinated regulation of target genes that are linked to congenital abnormalities. Together, these findings offer mechanistic insight into ASM-induced teratogenesis and support FA’s potential to mitigate epigenetic and proteomic disruptions. This integrated OMICs based approach identifies key biomarkers which can be used for therapeutic monitoring and help in optimizing maternal epilepsy management. Full article
(This article belongs to the Special Issue Genomics and Epigenomics in Molecular Neurobiology)
Show Figures

Graphical abstract

19 pages, 4405 KB  
Article
Photodegradation of Pyridine in a Fluidized Bed Photocatalytic Reactor Using Pt-ZnO Supported on Al2O3 as a Catalyst
by Ruby Gines, Carlos Montalvo, Guadalupe Luna, Daniel Montalvo, Rosa M. Cerón, Julia G. Cerón, Sinuhe Ginés, Aracely García and Claudia A. Aguilar
Catalysts 2025, 15(8), 772; https://doi.org/10.3390/catal15080772 - 13 Aug 2025
Viewed by 846
Abstract
Pyridine is a recalcitrant organic compound present in industrial wastewater that causes severe effects on the environment and the health of living beings, as it is considered a toxic, mutagenic, teratogenic, and carcinogenic agent. Therefore, this research explored the efficacy of a zinc [...] Read more.
Pyridine is a recalcitrant organic compound present in industrial wastewater that causes severe effects on the environment and the health of living beings, as it is considered a toxic, mutagenic, teratogenic, and carcinogenic agent. Therefore, this research explored the efficacy of a zinc oxide catalyst, doped with platinum nanoparticles and supported alumina through the precipitation method, for the photocatalytic degradation of pyridine using a fluidized bed reactor. A Box–Behnken experimental design was used to analyze the effect of the pH (4–10), the pyridine concentration (20–300 ppm), and the amount of catalyst (20–100 g). The X-ray diffraction (XRD) characterization results confirmed the hexagonal structure of the zinc oxide and the successful incorporation of platinum. Scanning electron microscopy (SEM) revealed a nano-bar morphology upon catalyst doping, favoring the photocatalytic activity. Pyridine removal of 57.7% was achieved under the following conditions: a pH of 4, 160 ppm of pyridine, and 100 g of catalyst. The process followed a pseudo-first-order model, obtaining the reaction constant k1 = 1.943 × 10−3 min−1 and the adsorption constant k2 = 1.527 × 10−3 L/mg. The results showed high efficiency and stability of the catalyst in the fluidized bed reactor for pyridine degradation, especially under acidic conditions, representing a promising technological alternative for treating industrial wastewater contaminated with N-heterocycles such as pyridine. Full article
(This article belongs to the Special Issue Advances in Photocatalytic Degradation)
Show Figures

Figure 1

11 pages, 1278 KB  
Article
Investigation of Low-Toxicity Azoic Direct Dyes Synthesized from 4,4′-Diaminobenzanilide
by Maria Elena Radulescu-Grad, Simona Popa, Giannin Mosoarca and Vasile Daniel Gherman
Processes 2025, 13(8), 2505; https://doi.org/10.3390/pr13082505 - 8 Aug 2025
Viewed by 436
Abstract
In this paper, a toxicological investigation was carried out on a series of azoic direct dyes generally with an affinity for cellulosic fibers, presenting symmetrical and asymmetrical structures having as a central component a non-carcinogenic, mutagenic, or teratogenic and accessible precursor potential substitute [...] Read more.
In this paper, a toxicological investigation was carried out on a series of azoic direct dyes generally with an affinity for cellulosic fibers, presenting symmetrical and asymmetrical structures having as a central component a non-carcinogenic, mutagenic, or teratogenic and accessible precursor potential substitute for benzidine, namely 4,4′-diaminobenzanilide, and, as coupling components, 2-hydroxybenzoic acid, 2-hydroxy-3,6-naphthalenesulfonic acid, 2-amino-8-hydroxynaphthalene-6-sulfonic acid, 1-amino-8-hydroxynaphthalene-3,6-disulfonic acid, 1-(4′-sulfophenyl)-3-methyl-5-pyrazolone, and 2-hydroxy-6-naphthalenesulfonic acid, respectively. For the purpose of their safe use, this study shows the results regarding the toxicity of the above-mentioned dyes, obtained through biological tests on colonies of Hydractinia echinata (H. echinata). The toxicity tests were performed on heterotrophic bacteria cultures obtained from the Bega River. The minimum toxic concentration was monitored using the dilutions 0.6 g/L, 24 g/L, and 48 g/L, obtained by dilution of a stock solution of 60 g/L. The symmetric dye with the coupling component 2-hydroxybenzoic acid presents the highest degree of toxicity, the lowest being shown by dyes with symmetric and asymmetric structures with the following coupling components: 2-amino-8-hydroxynaphthalene-6-sulfonic acid, 1-amino-8-hydroxynaphthalene-3,6-disulfonic acid, 1-(4′-sulfophenyl)-3-methyl-5-pyrazolone, and 2-hydroxy-6-naphthalenesulfonic acid. Full article
(This article belongs to the Section Biological Processes and Systems)
Show Figures

Figure 1

31 pages, 2032 KB  
Review
Leflunomide Applicability in Rheumatoid Arthritis: Drug Delivery Challenges and Emerging Formulation Strategies
by Ashish Dhiman and Kalpna Garkhal
Drugs Drug Candidates 2025, 4(3), 36; https://doi.org/10.3390/ddc4030036 - 1 Aug 2025
Cited by 1 | Viewed by 2297
Abstract
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder primarily targeting joints, leading to pain, swelling, and stiffness. RA results from the body’s own immune system attacking its own tissues. Currently, there are various treatments available for RA including disease-modifying antirheumatic drugs (DMARDs) [...] Read more.
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder primarily targeting joints, leading to pain, swelling, and stiffness. RA results from the body’s own immune system attacking its own tissues. Currently, there are various treatments available for RA including disease-modifying antirheumatic drugs (DMARDs) and NSAIDs. Leflunomide (LEF) is a USFDA-approved synthetic DMARD which is being widely prescribed for the management of RA; however, it faces several challenges such as prolonged drug elimination, hepatotoxicity, and others. LEF exerts its therapeutic effects by inhibiting dihydroorotate dehydrogenase (DHODH), thereby suppressing pyrimidine synthesis and modulating immune responses. Emerging nanotechnology-based therapies help in encountering the current challenges faced in LEF delivery to RA patients. This review enlists the LEF’s pharmacokinetics, mechanism of action, and clinical efficacy in RA management. A comparative analysis with methotrexate, biologics, and other targeted therapies, highlighting its role in monotherapy and combination regimens and the safety concerns, including hepatotoxicity, gastrointestinal effects, and teratogenicity, is discussed alongside recommended monitoring strategies. Additionally, emerging trends in novel formulations and drug delivery approaches are explored to enhance efficacy and minimize adverse effects. Overall, LEF remains a perfect remedy for RA patients, specifically individuals contraindicated with drugs like methotrexate. The therapeutic applicability of LEF could be enhanced by developing more customized treatments and advanced drug delivery approaches. Full article
(This article belongs to the Section Marketed Drugs)
Show Figures

Figure 1

27 pages, 5816 KB  
Article
Developmental Exposures to Three Mammalian Teratogens Produce Dysmorphic Phenotypes in Adult Caenorhabditis elegans
by Piper Reid Hunt, Martine Ferguson, Nicholas Olejnik, Jeffrey Yourick and Robert L. Sprando
Toxics 2025, 13(7), 589; https://doi.org/10.3390/toxics13070589 - 14 Jul 2025
Cited by 1 | Viewed by 927
Abstract
Efficient new methods are needed to support initiatives to reduce, refine, and/or replace toxicity testing in vertebrates. 5-fluorouracil (5FU), hydroxyurea (HU), and ribavirin (RV) are mammalian teratogens. Skeletal, endocrine organ, and cardiac effects are often associated with teratogenesis, and a simple nematode like [...] Read more.
Efficient new methods are needed to support initiatives to reduce, refine, and/or replace toxicity testing in vertebrates. 5-fluorouracil (5FU), hydroxyurea (HU), and ribavirin (RV) are mammalian teratogens. Skeletal, endocrine organ, and cardiac effects are often associated with teratogenesis, and a simple nematode like C. elegans lacks these systems. However, many genetic pathways required for mammalian morphogenesis have at least some conserved elements in this small, invertebrate model. The C. elegans lifecycle is 3 days. The effects of 5FU, HU, and RV on the C. elegans morphology were evaluated on day 4 post-initiation of the feeding after hatching for continuous and 24 h (early-only) developmental exposures. Continuous exposures to 5FU and HU induced increases in the incidences of abnormal gonadal structures that were significantly reduced in early-only exposure groups. The incidence of prolapse increased with continuous 5FU and HU exposures and was further increased in early-only exposure groups. Intestinal prolapse through the vulval muscle in C. elegans may be related to reported 5FU and HU effects on skeletal muscle and the gastrointestinal tract in mammals. Continuous RV exposures induced a phenotype lacking a uterus and gonad arms, as well as vulval anomalies that were largely, but not completely, reversed with early-only exposures, which is consistent with reported reversible reproductive tract anomalies after an RV exposure in mammals. These findings suggest that C. elegans can be used to detect the hazard risk from chemicals that adversely affect conserved pathways involved in organismal morphogenesis, but to determine the fit-for-purpose use of this model in chemical safety evaluations, further studies using larger and more diverse chemical test panels are needed. Full article
(This article belongs to the Section Novel Methods in Toxicology Research)
Show Figures

Graphical abstract

18 pages, 14857 KB  
Article
Valproic Acid Promotes the Differentiation of Satellite Glial Cells into Neurons via the pH-Dependent Pathway
by Dongyan Wang, Wenrun Kang, Jinhui Zhang, Jianwei Xu, Ruyi Wang, Xiangdan Xiao, Chao Wei, Wenfeng Yu and Junhou Lu
Biomolecules 2025, 15(7), 986; https://doi.org/10.3390/biom15070986 - 11 Jul 2025
Viewed by 628
Abstract
Valproic acid (VPA) is a widely prescribed antiepileptic agent whose teratogenic potential has been recognized. In recent years, VPA has been shown to promote neuronal regeneration; however, the exact molecular mechanisms are not fully understood. This study elucidates the pH-dependent pathway through which [...] Read more.
Valproic acid (VPA) is a widely prescribed antiepileptic agent whose teratogenic potential has been recognized. In recent years, VPA has been shown to promote neuronal regeneration; however, the exact molecular mechanisms are not fully understood. This study elucidates the pH-dependent pathway through which VPA promotes the differentiation of satellite glial cells (SGCs) into neurons. We observed sustained intracellular pH elevation during the VPA-induced neural differentiation of SGCs, and the modulation of intracellular pH was shown to influence this differentiation process. Then, we found that VPA regulates intracellular pH through NHE1 (sodium–hydrogen exchanger 1), and that the pharmacological inhibition of NHE1 not only attenuated intracellular pH elevation but also substantially impaired VPA-induced neuronal differentiation. Finally, our results showed that the elevated intracellular pH promoted the neuronal differentiation of SGCs by activating β-catenin signaling. These findings provide novel insights into the mechanisms of VPA-induced neurogenesis, advancing our understanding of its pharmacological profile and informing its potential therapeutic application in neuronal regeneration strategies. Full article
(This article belongs to the Section Cellular Biochemistry)
Show Figures

Figure 1

11 pages, 201 KB  
Article
Adverse Effects and Precautionary Measures for Isotretinoin Use in Patients with Acne Vulgaris: A Single-Center Study
by Mohammed Saif Anaam, Dalia A. AlShibl, Saeed Alfadly, Munirah Yousef Aloyuni, Fawaz Hamdan Al Harbi, Hussam Alhmoud, Ibrahim S. Alhomoud and Waleed Mohammad Altowayan
Healthcare 2025, 13(13), 1617; https://doi.org/10.3390/healthcare13131617 - 7 Jul 2025
Viewed by 2000
Abstract
Background: Oral isotretinoin is an effective treatment for refractory and moderate acne unresponsive to conventional therapies, considered the most effective option for such cases. Objective: This study aimed to evaluate the knowledge, concerns, and experiences of acne patients undergoing isotretinoin treatment in Qassim, [...] Read more.
Background: Oral isotretinoin is an effective treatment for refractory and moderate acne unresponsive to conventional therapies, considered the most effective option for such cases. Objective: This study aimed to evaluate the knowledge, concerns, and experiences of acne patients undergoing isotretinoin treatment in Qassim, Saudi Arabia, with a focus on commonly reported adverse effects. Methods: A cross-sectional study was conducted from December 2023 to February 2024 using a self-administered questionnaire. This study targeted male and female acne vulgaris patients from the Qassim region attending the outpatient dermatology clinic at King Saud Hospital (KSH). Results: A total of 131 acne patients participated. Of these, 97.7% had heard of isotretinoin, and 92.4% were aware of its side effects. The most common sources of information were colleagues, friends, or family (37.4%), followed by previous use (26%) and healthcare professionals (24%). The most frequently reported side effect was dryness (51.9%), followed by liver function changes (24.4%) and fetal abnormalities (13%). There was a significant association between educational level and knowledge of isotretinoin’s side effects (p = 0.003) and awareness of specific side effects (p < 0.001). Conclusion: Most acne patients had sufficient knowledge of isotretinoin and its adverse effects, with dryness being the most commonly reported side effect. The primary sources of information were non-medical, highlighting the need for health education to ensure informed and safe isotretinoin use. Full article
Back to TopTop